Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer

Inclusion Criteria: * ECOG Performance Status (PS) ≤1 * Histologically or cytologically confirmed, unresectable metastatic colorectal cancer * Measurable disease by RECIST guidelines * Evidence of disease progression following first-line therapy with a fluoropyrimidine, oxaliplatin, and bevacizumab (≤ 8 weeks since last dose) * Available paraffin embedded tumor tissue * Willing to give a whole blood sample for the study of proteins and genetic polymorphisms Exclusion Criteria: * Less than 28 days elapsed since major surgery at time of randomization * Known CNS metastases * Excessive risk of bleeding (including use of therapeutic anticoagulation other than low dose aspirin) and history of thrombotic or embolic cerebrovascular accident * Uncontrolled hypertension * Clinically significant cardiovascular disease * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months * Serious non-healing wound, active peptic ulcer, non-healing bone fracture, or bleeding skin metastasis * Known HIV Positive